<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03738358</url>
  </required_header>
  <id_info>
    <org_study_id>2016-02-015</org_study_id>
    <nct_id>NCT03738358</nct_id>
  </id_info>
  <brief_title>Clinical Study of 12-week Trehalose Intake in Patients With Fatty Liver Disease</brief_title>
  <official_title>A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of Trehalose in Patients With Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will be conducted to evaluate the efficacy and safety of trehalose in
      patients with fatty liver disease. After 12-week intake, subjects will be checked up fat
      content in liver using CT scan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Actual">March 20, 2018</completion_date>
  <primary_completion_date type="Actual">March 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in liver fat content scanned by CT</measure>
    <time_frame>Screening (baseline) and 12 weeks</time_frame>
    <description>Trehalose group and placebo comparator group are scanned by CT to compare the difference of liver fat content</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ALT and AST</measure>
    <time_frame>0 (baseline) and 12 weeks</time_frame>
    <description>Change from baseline of ALT and AST, the trend of change in blood, the proportion of subjects with normal ALT and AST level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in homeostatic model assessment-insulin resistance (HOMA-IR)</measure>
    <time_frame>Screening (baseline) and 12 weeks</time_frame>
    <description>Change from baseline of HOMA-IR, the trend of change in blood, the proportion of subjects with normal HOMA-IR level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total cholesterol, LDL, HDL, triglyceride (TG) and free fatty acid</measure>
    <time_frame>0 (baseline), 6 and 12 weeks</time_frame>
    <description>the trend of change in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
    <time_frame>0 (baseline), 6 and 12 weeks</time_frame>
    <description>BMI among subjects is measured by physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral fat and subcutaneous fat levels</measure>
    <time_frame>0 week and 12 weeks</time_frame>
    <description>Both visceral fat and subcutaneous fat levels are anlayzed by CT scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event (AE)</measure>
    <time_frame>0 week, 6 weeks, and 12 weeks</time_frame>
    <description>Symptom and signs in subjects are monitored</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Non-alcoholic Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Trehalose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Trehalose</intervention_name>
    <description>80 mL pouch/day for 12 weeks, containing trehalose 5 g, water 74.92 g and scent additive 0.08 g</description>
    <arm_group_label>Trehalose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>80 mL pouch/day for 12 weeks, containing water 79.92 g and scent additive 0.08 g</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 19-year-old and 79-year-old

          -  Weight (â‰¥50kg)

          -  Is diagnosed as fatty liver on ultrasonography within 24 weeks from screening day

          -  Has willingness and ability to participate whole clinical study period

          -  Willing to give informed consent form

        Exclusion Criteria:

          -  Patient with alcoholic fatty liver

          -  Patient with inflammatory bowel disease

          -  Is required treatment for like liver, kidney, digestive system, circulatory system,
             respiratory system, endocrine system(except diabetes), musculoskeletal,
             neuropsychiatry, or hemato-oncology etc., which is able to effect on clinical study

          -  Has any medical history with virus or toxic hepatitis

          -  Has any medical history of gastrointestinal surgery (except simple appendectomy &amp;
             repair of hernia)

          -  Has medical history of malignant tumor (except non-melanoma skin cancer) within the
             last 5 years from the screening day

          -  Took any drugs (UDCA, silymarin, omega-3, fenofibrate etc.) which is decided as
             unsuitable drug for combined-dose by investigator

          -  Over 4 times of maximum reference range of ALT or AST

          -  Average drinking quantity per week &gt; alcohol 140 g

          -  Pregnant or nursing women

          -  Is currently participating into another clinical study

          -  Being made a decision from investigator as unsuitable to participate this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jung-Ryul Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

